Cannabics' RCC-33 prolongs survival rate in mice inoculated with human colorectal cancer cells

Stock Information for CNBX Pharmaceuticals Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CNBX Pharmaceuticals Inc

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel
CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate
CNBX Pharmaceuticals Announces New Patent Granted in Australia
CNBX Pharmaceuticals Granted Patent in Hong Kong
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.